Logo

Ronald Andrews

Jun 06, 2019

OncoCyte has appointed Ronald Andrews as its CEO, effective July 1. In addition to serving as a board member at OncoCyte, Andrews has over 30 years of experience in the clinical and molecular diagnostics field. OncoCyte's current CEO, William Annett, will remain with the company in an advisory role.

Prior to joining the firm, Andrews was the founder and principal of the Bethesda Group. Before Bethesda, he served as Thermo Fisher Scientific's genetic science division president, where he oversaw the integration of Life Technologies' genetic platform. He also served as president of Life Tech's Medical Science Venture. Before joining Life Tech, Andrews acted as CEO at Clarient (formerly ChromaVision Medical Systems), which was sold to GE Healthcare in 2010. He subsequently served as GE Molecular Diagnostics' CEO until 2011. Andrews also held various senior executive roles at Roche Diagnostics from 2000 to 2004. Andrews served as VP of marketing at Immucor from 1995 to 2000. Prior to Immucor, Andrews spent about 10 years in management positions at Abbott Diagnostics.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.